Trimethoprim (Alprim) - Uses, Dose, Side effects, MOA, Brands

Trimethoprim (Alprim) is an antibiotic that acts by inhibiting bacterial folate activation to tetrahydrofolate inhibiting bacterial protein and nucleic acid synthesis. It is used in the treatment of acute urinary tract infection, otitis media, and pneumocystis pneumonia infection.

Trimethoprim Uses:

  • Treatment of uncomplicated acute Cystitis (tablets, oral solution):

    • It is indicated for the treatment of uncomplicated urinary tract infections caused by susceptible strains of the following organisms:
      • Escherichia coli,
      • Proteus mirabilis,
      • Klebsiella pneumoniae,
      • Enterobacter species and
      • coagulase-negative Staphylococcus species, including S. saprophyticus.
  • Acute Otitis media (oral solution):

    • It is used to treat acute otitis media in children caused by susceptible strains of Streptococcus pneumoniae and Haemophilus influenzae.
  • Off Label Use of Trimethoprim in Adults:

    • Acne vulgaris;
    • Treatment of mild to moderately severe pneumocystis pneumonia infection;
    • Prophylaxis of urinary tract infection.

Trimethoprim (Alprim) Dose in Adults

Trimethoprim (Alprim) Dose in the treatment of treatment of acute uncomplicated Cystitis:

  • 100 mg orally twice daily for 3 days.
  • Manufacturer's labeling:

    • 200 mg once a day (The dosing mentioned here may not reflect the current practice guidelines).

Trimethoprim (Alprim) Dose in the treatment of Acne vulgaris as an alternative therapy (off-label):

  • 100 mg orally thrice daily or 300 mg two times a day.
  • Treatment should be given for the shortest possible time to minimize bacterial resistance. Patients must be evaluated every three to four months.

Trimethoprim (Alprim) Dose as an alternative agent in the treatment of mild to moderate Pneumocystis pneumonia (off-label use):

  • Oral: 15 mg/kg/day in three divided doses in combination with dapsone for 21 days.

Trimethoprim (Alprim) Dose for the prophylaxis of uncomplicated Urinary tract infection (off-label):

  • 100 mg orally once a day.

Trimethoprim (Alprim) Dose in Childrens

Trimethoprim (Alprim) Dose in the treatment of acute Otitis media:

  • Infants ≥6 months, Children, and Adolescents:

    • 10 mg/kg/day orally in two divided doses administered every 12 hours for ten days.
    • The maximum daily dose is 400 mg/day.

Trimethoprim (Alprim) Dose in the treatment of uncomplicated urinary tract infection:

  • Infants ≥2 months, Children, and Adolescents:

Trimethoprim (Alprim) Dose in the treatment of Pneumocystis jirovecii pneumonia (PCP):

  • Children and Adolescents:

    • 15 mg/kg/day orally in three divided doses in combination with dapsone for 21 days.
    • Data in children is limited. The combination product, sulfamethoxazole and trimethoprim is preferred.

Pregnancy Risk Factor C

  • It may cross the placental boundary. It can cause adverse fetal outcomes due to its effect on folate metabolism.
  • Also, read the sulfamethoxazole/trimethoprim monograph for details

Trimethoprim use during breastfeeding:

  • Breast milk contains the drug, and its concentration is identical in maternal blood and breastmilk.
  • Breastmilk can contain antibiotics which may cause side effects, such as diarrhea and oral thrush.
  • It can also interfere with folate metabolism and is not recommended for breastfeeding.
  • Products that do not contain the combination (trimethoprim) are compatible with breastfeeding.
  • Also, read septran.

Dose in Kidney Disease:

  • Manufacturer's labeling:

    • CrCl >30 mL/minute: Use with caution, however, no dosage adjustment is necessary.
    • CrCl 15 to 30 mL/minute: Administer half of the recommended dose.
    • CrCl <15 mL/minute: Avoid in advanced renal disease.
  • Alternate recommendations:

    • Aronoff 2007: Note: Dose adjustments mentioned here are based on the usual daily dose of 100 mg twice a day.
      • CrCl >30 mL/minute: No dosage adjustment necessary.
      • CrCl 10 to 30 mL/minute: 100 mg administered every 18 hours.
    • CrCl <10 mL/minute: 100 mg once a day.
    • Intermittent Hemodialysis: It is 20% to 59% dialyzable. Administration of the dose after dialysis is recommended.
    • Peritoneal dialysis: 100 mg once a day.
  • HHS (OI adult 2019):

    • Treatment of Pneumocystis pneumonia:
      • Note: Dosage adjustments mentioned here are based on the usual maintenance dose of 5 mg/kg administered every 8 hours. Renal function may be estimated using the Cockcroft-Gault formula for dosage adjustment purposes.
      • CrCl >30 mL/minute: No dosage adjustment necessary.
      • CrCl 10 to 30 mL/minute: 5 mg/kg twice daily.
      • CrCl <10 mL/minute: 5 mg/kg once daily.
      • Intermittent Hemodialysis:
        • It is moderately dialyzable, about 20% to 59%.
        • 5 mg/kg once daily. The dose is administered after hemodialysis on the day of dialysis.

Dose in Liver disease:

There are no dosage adjustments provided in the manufacturer’s labeling. It should be used with caution in patients with liver disease. 

Side effects of Trimethoprim (Alprim):

  • Dermatologic:

    • Maculopapular Rash
    • Phototoxicity
    • Pruritus
  • Endocrine & Metabolic:

    • Hyperkalemia
    • Hyponatremia
  • Gastrointestinal:

    • Epigastric Distress
    • Glossitis
    • Nausea
    • Vomiting
  • Hematologic & Oncologic:

    • Leukopenia
    • Megaloblastic Anemia
    • Methemoglobinemia
    • Neutropenia
    • Thrombocytopenia
  • Hepatic:

    • Increased Liver Enzymes
  • Hypersensitivity:

    • Anaphylaxis
    • Hypersensitivity Reaction
  • Renal:

    • Increased Blood Urea Nitrogen
    • Increased Serum Creatinine
  • Miscellaneous:

    • Fever

Contraindications to Trimethoprim (Alprim):

  • Allergy reactions to trimethoprim and any component of the formulation
  • Megaloblastic anemia due to folate deficiency

Warnings and precautions

  • Hematologic effects

    • Long-term treatment or high doses of medication may lead to cytopenias, bone marrow suppression, and even death.
    • Long-term therapy patients should be closely monitored for signs and symptoms of bone tumor suppresion.
  • Hyperkalemia:

    • Treatment may result in hyperkalemia. Hyperkalemia is a risk for patients who are:
      • High doses (above 20 mg/kg/day)
      • Patients with severe renal impairment
      • Ageing is a good thing
      • Hypoaldosteronism is a form of and
      • Patients taking concomitant medication that can cause or exacerbate hyperkalemia.
  • Hypersensitivity

    • Rarely, severe allergic reactions can occur.
  • Superinfection

    • Long-term use can lead to superinfections, including fungal or bacterial infections.
    • Patients receiving long-term treatment may experience pseudomembranous colitis and C. difficile-associated diarrhea. 
    • This may occur up to two months after the last treatment.
  • Hepatic impairment

    • Patients with hepatic impairment need to be cautious.
  • Renal impairment

    • It should be used with caution by patients with impaired renal function.

Trimethoprim: Drug Interaction

Risk Factor C (Monitor therapy)

Alpelisib

May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers).

Amantadine

Trimethoprim may enhance the adverse/toxic effect of Amantadine. Specifically, the risk of myoclonus and/or delirium may be increased. Amantadine may increase the serum concentration of Trimethoprim. Trimethoprim may increase the serum concentration of Amantadine.

Angiotensin II Receptor Blockers

Trimethoprim may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.

Angiotensin-Converting Enzyme Inhibitors

Trimethoprim may enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.

AzaTHIOprine

Trimethoprim may enhance the myelosuppressive effect of AzaTHIOprine.

BCG Vaccine (Immunization)

Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization).

CYP2C9 Inhibitors (Moderate)

May decrease the metabolism of CYP2C9 Substrates (High risk with Inhibitors).

Dapsone (Systemic)

Trimethoprim may increase the serum concentration of Dapsone (Systemic). Dapsone (Systemic) may increase the serum concentration of Trimethoprim.

Dapsone (Topical)

Trimethoprim may enhance the adverse/toxic effect of Dapsone (Topical). More specifically, trimethoprim may increase the risk for hemolysis

Digoxin

Trimethoprim may increase the serum concentration of Digoxin.

Eplerenone

Trimethoprim may enhance the hyperkalemic effect of Eplerenone.

Lactobacillus and Estriol

Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol.

LamiVUDine

Trimethoprim may increase the serum concentration of LamiVUDine.

Lumacaftor

May decrease the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers). Lumacaftor may increase the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers).

Memantine

Trimethoprim may enhance the adverse/toxic effect of Memantine. Specifically, the risk of myoclonus and/or delirium may be increased. Trimethoprim may increase the serum concentration of Memantine. Memantine may increase the serum concentration of Trimethoprim.

Mercaptopurine

Trimethoprim may enhance the myelosuppressive effect of Mercaptopurine.

MetFORMIN

Trimethoprim may increase the serum concentration of MetFORMIN.

PRALAtrexate

Trimethoprim may increase the serum concentration of PRALAtrexate. More specifically, trimethoprim may decrease excretion of pralatrexate. Management: Closely monitor for increased pralatrexate serum level and/or possible toxicity with concomitant use of trimethoprim. Monitor for decreased pralatrexate levels with discontinuation of trimethoprim.

Pyrimethamine

May enhance the adverse/toxic effect of Trimethoprim.

Repaglinide

Trimethoprim may decrease the metabolism of Repaglinide.

RifAMPin

May decrease the serum concentration of Trimethoprim.

Rifapentine

May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers).

Spironolactone

Trimethoprim may enhance the hyperkalemic effect of Spironolactone.

Thiazolidinediones

Trimethoprim may decrease the metabolism of Thiazolidinediones.

Varenicline

Trimethoprim may increase the serum concentration of Varenicline. Management: Monitor for increased varenicline adverse effects with concomitant use of trimethoprim, particularly in patients with severe renal impairment. International product labeling recommendations vary. Consult appropriate labeling.

Risk Factor D (Consider therapy modification)

Dabrafenib

May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP2C9 substrate when possible. If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).

Enzalutamide

May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP2C9 substrates that have a narrow therapeutic index should be avoided. Use of enzalutamide and any other CYP2C9 substrate should be performed with caution and close monitoring.

Fosphenytoin

May decrease the serum concentration of Trimethoprim. Trimethoprim may increase the serum concentration of Fosphenytoin. Management: Consider alternatives to this combination when possible, to avoid potential decreased trimethoprim efficacy and increased phenytoin concentrations/effects. Monitor patients receiving this combination closely for both of these possible effects.

Methotrexate

Trimethoprim may enhance the adverse/toxic effect of Methotrexate. Management: Consider avoiding concomitant use of methotrexate and either sulfamethoxazole or trimethoprim. If used concomitantly, monitor for the development of signs and symptoms of methotrexate toxicity (e.g., bone marrow suppression).

MiFEPRIStone

May increase the serum concentration of CYP2C9 Substrates (High risk with Inhibitors). Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.

Phenytoin

Trimethoprim may increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Trimethoprim. Management: Consider alternatives to this combination when possible, to avoid potential decreased trimethoprim efficacy and increased phenytoin concentrations/effects. Monitor patients receiving this combination closely for both of these possible effects.

Procainamide

Trimethoprim may increase serum concentrations of the active metabolite(s) of Procainamide. Trimethoprim may increase the serum concentration of Procainamide.

Sodium Picosulfate

Antibiotics may diminish the therapeutic effect of Sodium Picosulfate. Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.

Typhoid Vaccine

Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected. Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents. Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.

Risk Factor X (Avoid combination)

Amodiaquine

Trimethoprim may enhance the neutropenic effect of Amodiaquine. Trimethoprim may increase the serum concentration of Amodiaquine.

BCG (Intravesical)

Antibiotics may diminish the therapeutic effect of BCG (Intravesical).

Cholera Vaccine

Antibiotics may diminish the therapeutic effect of Cholera Vaccine. Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.

Dofetilide

Trimethoprim may increase the serum concentration of Dofetilide.

Leucovorin Calcium-Levoleucovorin

May diminish the therapeutic effect of Trimethoprim. Management: Avoid concurrent use of leucovorin or levoleucovorin with trimethoprim (plus sulfamethoxazole) for Pneumocystis jirovecii pneumonia. If trimethoprim is used for another indication, monitor closely for reduced efficacy.

Monitoring parameters:

Monitor CBC with differential counts, platelet count, liver function tests, bilirubin, serum potassium, serum creatinine, and BUN periodically in patients on long-term treatment.

How to administer Trimethoprim (Alprim)?

  • It is administered without regard to meals.
  • It may be administered with food or milk to reduce the gastrointestinal side effects. 

Mechanism of action of Trimethoprim (Alprim):

  • It inhibits bacterial nucleic acids synthesis and proteins by reversibly inhibiting dihydrofolate reductase. 
  • This causes the inhibition of folic acids conversion to tetrahydrofolate, which is active folate. It is necessary for the production of nucleic acids and proteins in bacteria.

Absorption:

  • When taken orally, it is easily absorbed.

Distribution:

  • It is found in many body tissues and fluids, including the middle ear, CSF, Bile and prostate.

Protein binding:

  • About 44%

Metabolism:

  • It is partially metabolized in the liver (10% to 20%) via demethylation, oxidation, and hydroxylation

Bioavailability:

  • Similar for tablets and solution

Half-life elimination:

  • Half-life elimination is prolonged with renal impairment
  • Newborns: 19 hours (range: 11 to 27 hours)
  • Infants 2 months to 1 year: 4.6 hours (range: 3 to 6 hours)
  • Children:
    • 1 to 3 years: 3.7 hours
    • 8 to 10 years: 5.4 hours
  • Adults with normal renal function: 8 to 10 hours

Time to peak serum concentration:

  • 1 to 4 hours

Excretion:

  • It is primarily excreted in urine (50% to 60%; 80% as unchanged drug);
  • feces

International Brand Names of Trimethoprim:

  • Primsol
  • Trimpex
  • Abaprim
  • Alprim
  • Antrin
  • Catin
  • Epirim
  • Giprim
  • Idotrim
  • Infectotrimet
  • Monotrim
  • Motrim
  • Primosept
  • Sinersul
  • Solotrim
  • Sulotrim
  • Tediprima
  • Tobyprim
  • Trimcort
  • Trimesan
  • Trimetin
  • Trimetop
  • Trimetoprim
  • Trimol-A
  • Trimopan
  • Trimoptin
  • Triprim
  • Urotrim
  • Utisept
  • Wellcoprim

Trimethoprim Brand Names in Pakistan:

Trimethoprim Suspension 80 mg in Pakistan

Zoprim-Ds Atlantic Pharmaceuticals (Pvt) Ltd.

 

Trimethoprim Suspension 40 mg/5ml in Pakistan

Royamax Semos Pharmaceuticals (Pvt) Ltd.
Zoprim Atlantic Pharmaceuticals (Pvt) Ltd.

 

Trimethoprim Tablets 160 mg in Pakistan

Incot-Ds Innvotek Pharmaceuticals

 

Trimethoprim Tablets 300 mg in Pakistan

Syraprim Glaxosmithkline

Comments

NO Comments Found